BETonMACE Looks at BET Protein Inhibition ACS and Diabetes
(World News USA)

Treatment with apabetalone - the first in class bromodomain and extra-terminal (BET) inhibitor - in patients who had acute coronary syndrome (ACS) with type 2 diabetes and low HDL-C `shows promise,` according to results of the BETonMACE trial presented Nov. 16 during AHA 2019 in Philadelphia, PA. Kausik K. Ray, MD, FACC, et al., looked at 2,425 patients at 195 sites in 13...